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In traditional Materia Medica, Gelsemium 
sempervirens (G. sempervirens) is described 
as a remedy for a variety of anxiety-like 
psychological and behavioral symptoms, 
however consistent evidence of its efficacy 
is lacking. In our recent experimental stud-
ies (Bellavite et al., 2009; Magnani et al., 
2010), groups of CD1 mice were treated 
with highly diluted solutions of G. sem-
pervirens, or with conventional anxiolytic 
drugs, or with a placebo consisting of only 
the solvent (control groups). The results 
showed that G. sempervirens reduced anxi-
ety and fear in a manner quantitatively 
comparable to the effects of normal anxi-
olytic drugs, but without provoking any 
sedation side-effects (which instead did 
occur with buspirone in that experimental 
set-up). These findings are consistent with 
those obtained by a group at the University 
of Strasbourg, which found that the same 
plant compound had a direct effect on 
the production of allopregnanolone by 
rat neurons grown in cell culture plates 
(Venard et al., 2009). Thus it is likely that 
the mechanism involved is the regulation 
of production of endogenous neuroster-
oids through glycinergic receptors. The 
chief innovation of this line of research lies 
in the fact that, until now, natural remedies 
based on G. sempervirens had been used 
only on humans, but without consistent 
evidence of efficacy or with controversial 
results. Since these remedies also appear 
to work on animal models and on in vitro 
systems, this indicates that they do not 
have merely a “placebo” effect, and that 
this type of pharmacology using ultra low 
doses – referred also as “nanopharmacol-
ogy” – merits further investigation and 
validation.
The “commentary” entitled “Gelsemine 
and G. sempervirens L. extracts in animal 
behavioral test: comments and related 
biases” (Chirumbolo, 2011) is explicitly 
announced as a commentary on a recent 
paper from our research group (Magnani et 
al., 2010). The commentary does not make 
clear which are the contested points, nor the 
reason for the imputation of “related biases” 
in the title of the letter. The author main-
tains that “no pharmacological studies eval-
uated anti-anxiety activity of Gelsemium 
prior to the recently reported evidence of 
Dutt et al. (2010)” In point of fact, our first 
results on this subject were published in 
2009 (Bellavite et al., 2009).
In the first part of the text, the author 
dwells at length upon the toxicity of the plant 
and of one of its active principles, gelsemine. 
These facts are well-known in the literature, 
but have no bearing on the question of the 
pharmacological effect on animal behavior, 
which in the research addressed by this com-
mentary (Magnani et al., 2010), and in oth-
ers cited therein (Venard et al., 2008, 2009), 
is accomplished through the administration 
of extremely low doses that are expected to 
be non-toxic. According to literature, in 
emergencies due to Gelsemium poisoning, 
gelsemine was sustained as the main marker 
of toxicity and was detected in the urine at 
concentrations ranging from 10 to 120 ng/
ml (Lai and Chan, 2009); as a matter of facts, 
in our studies, the maximum concentration 
of gelsemine in the drug samples tested (pre-
cisely in the fourth centesimal dilution from 
mother tincture) was 0.0021 ng/ml and we 
administered 0.3 ml to 30 g weighing mice, 
with a further dilution of about 100-fold 
assuming uniform distribution. In any case, 
since no clinical data about potential adverse 
effects of G. sempervirens for chronic use in 
humans are available, the safety issue needs 
to be better addressed.
The commentary correctly reports that 
our work has demonstrated anxiolytic 
effects of high dilutions of G. sempervirens 
using two behavioral tests, the open field 
(OF) and light–dark (LD) tests, but then 
notes that “effects in the elevated plus-
maze, an assay considered to be important 
in behavioral assessment of potential anxio-
lytic compounds, have not been assessed.” 
The author of the commentary should 
know that there exist dozens of tests for 
animal behavior, out of which each proto-
col employs, for theoretical and practical 
reasons, whichever ones the experimenter 
deems best suited for the purposes of the 
research. OF (Prut and Belzung, 2003) and 
LD (Bourin and Hascoet, 2003) are two 
validated animal models, which allow to 
acquire various behavioral parameters and 
are widely employed in neuropsychophar-
macology for drug screening (Belzung and 
Griebel, 2001; Bourin et al., 2007). Classic 
anxiolytics (benzodiazepines) as well as the 
newer anxiolytic-like compounds (e.g., ser-
otonergic drugs) and natural compounds 
(Chen et al., 2004) have been tested using 
these paradigms. Therefore, the five differ-
ent behavioral variables extracted from OF 
and LD in our investigation are sufficient 
and demonstrative enough of the psychop-
harmacological effect, although in the view 
of the results of our study it is not unrea-
sonable to envisage the use of additional 
complementary tests for future studies on 
this topic.
Immediately afterward in the com-
mentary we read that “Actually, the physi-
cal integration of different current tests in 
one single apparatus, should contribute 
to increased reliability, rapidity, and com-
prehensiveness in behavioral testing.” This 
might at first glance seem a good idea; but 
in reality, every researcher in the field of 
experimental psychopharmacology knows 
that each model must be validated and is 
designed to evaluate different parameters. 
No-one has ever dreamed of using an appa-
ratus which “physically integrates” OF, LD, 
and the elevated plus-maze.
The crux of the matter is reached when 
the author maintains that “criticism may be 
raised about biases in their experimental 
context,” citing the works of Venard (Venard 
et al., 2008, 2009) and of our own group 
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 psychopharmacology. With respect to our 
work, it is false (most experiments gave 
positive results and the ANOVA was highly 
significant) and ungrounded because it is 
impossible for Chirumbolo to have com-
puted the 10–20% percent of tests from 
our data which are supplied as popula-
tion averages. Moreover, in our work we 
clearly specify that the power of the study 
needed to achieve statistical certainty was 
correctly computed before undertaking 
the trials.
We obviously agree with Chirumbolo’s 
conclusion that “Certainly, research on the 
anti-anxiety potential of Gelsemium alka-
loids needs further investigative efforts, in 
order to comprehend the role of this plant 
in neuropharmacology,” and await other 
experimental contributions, however it 
certainly does not constitute a criticism of 
our work.
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(Magnani et al., 2010). The author dwells at 
length on the effects of the active principle 
gelsemine, but puts forward no arguments in 
support of his claim of possible “bias” in the 
research, so that this assertion is impossible 
to discuss or controvert. In the central para-
graph of the commentary, we find a treatise 
on the “placebo” and “nocebo” effects (all 
well-known phenomena in pharmacology), 
but not applicable to the work in question, 
which adopted rigorous double blind con-
trols, consisting of the same solvent as the 
drug but without the active principle, pre-
cisely to rule out these types of effects. The 
net effect of the drug was always calculated 
as a percentage relative to the behavioral 
parameter measured in the mice treated 
with placebo. Indeed in the discussed study 
appropriate blinding, dummy medication, 
positive controls, and similar testing envi-
ronment for all conditions were used. These 
measures are be sufficient to minimize pla-
cebo/nocebo biases.
Finally, the author implies – without 
demonstrating it – that there might be a 
bias in the statistics, where he maintains 
that “according to some Authors, the sta-
tistical power of behavioral studies to 
detect relationships is quite low: the power 
to detect a medium effect is 39–47% and 
in this case only 10–20% of tests exceeded 
the recommended minimum criterion of 
80%, as assessed by Cohen and colleagues.” 
This assertion is in general terms highly 
debatable, and by no means endorsed 
by researchers in the field of behavioral 
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